{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:37:05Z","timestamp":1787773025130,"version":"build-2784847793"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.yebeh.2023.109173","type":"journal-article","created":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T12:09:56Z","timestamp":1680350996000},"page":"109173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE)"],"prefix":"10.1016","volume":"142","author":[{"given":"Scott","family":"Demarest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafali","family":"Jeste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Arkilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Asgharnejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Thibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2023.109173_b0005","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2018.05.013","article-title":"Open-label use of highly purified CBD (Epidiolex\u00ae) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes","volume":"86","author":"Devinsky","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109173_b0010","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1093\/brain\/awz195","article-title":"Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort","volume":"142","author":"Symonds","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.yebeh.2023.109173_b0015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109173_b0020","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ajhg.2017.09.008","article-title":"High rate of recurrent de novo mutations in developmental and epileptic encephalopathies","volume":"101","author":"Hamdan","year":"2017","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.yebeh.2023.109173_b0025","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.pcl.2015.03.004","article-title":"Prader-Willi, Angelman, and 15q11-q13 duplication syndromes","volume":"62","author":"Kalsner","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.yebeh.2023.109173_b0030","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/epi.12530","article-title":"A survey of seizures and current treatments in 15q duplication syndrome","volume":"55","author":"Conant","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109173_b0035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-3-30","article-title":"The inv dup (15) or idic (15) syndrome (Tetrasomy 15q)","volume":"3","author":"Battaglia","year":"2008","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.yebeh.2023.109173_b0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2019.02.015","article-title":"Cyclin-dependent kinase-like 5 deficiency disorder: clinical review","volume":"97","author":"Olson","year":"2019","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2023.109173_b0045","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/ejhg.2012.156","article-title":"The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy","volume":"21","author":"Fehr","year":"2013","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.yebeh.2023.109173_b0050","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s11689-021-09384-z","article-title":"Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder","volume":"13","author":"Olson","year":"2021","journal-title":"J Neurodev Disord"},{"key":"10.1016\/j.yebeh.2023.109173_b0055","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1177\/08830738211019284","article-title":"Cerebral visual impairment in CDKL5 deficiency disorder correlates with developmental achievement","volume":"36","author":"Brock","year":"2021","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2023.109173_b0060","doi-asserted-by":"crossref","first-page":"17081","DOI":"10.1038\/s41598-020-74036-6","article-title":"Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice","volume":"10","author":"Nishi","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.yebeh.2023.109173_b0065","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejpn.2015.09.001","article-title":"Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy","volume":"20","author":"M\u00fcller","year":"2016","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2023.109173_b0070","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1111\/bcp.14854","article-title":"Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects","volume":"87","author":"Wang","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2023.109173_b0075","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1111\/bcp.15225","article-title":"Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers","volume":"88","author":"Wang","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2023.109173_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106646","article-title":"A phase 1b\/2a study of soticlestat as adjunctive therapy in participants with developmental and\/or epileptic encephalopathies","volume":"174","author":"Halford","year":"2021","journal-title":"Epilepsy Res"},{"issue":"5","key":"10.1016\/j.yebeh.2023.109173_b0085","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1474-4422(22)00077-1","article-title":"Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Knight","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2023.109173_b0090","unstructured":"Yin W, Dong C, Stevenson A, Lloyd V, Petrillo M, Baratta M, et al. Effects of itraconazole, mefenamic Acid and rifampicin on the pharmacokinetics of the CH24H inhibitor soticlestat: two drug-drug interaction studies in healthy volunteers, https:\/\/cms.aesnet.org\/abstractslisting\/effects-of-itraconazole--mefenamic-acid-and-rifampicin-on-the-pharmacokinetics-of-the-ch24h-inhibitor-soticlestat--two-drug%E2%80%93drug-interaction-studies-in-healthy-volunteers [accessed Jan 9, 2023]."},{"key":"10.1016\/j.yebeh.2023.109173_b0095","unstructured":"Andrews JS, Nacson A, Sams L, Symonds T, Beumont J, Asgharnejad M, et al. Development of a novel clinical global impression measure for clinical outcome assessment of nonseizure symptoms in Lennox\u2013Gastaut syndrome and Dravet syndrome, https:\/\/cms.aesnet.org\/abstractslisting\/development-of-a-novel-clinical-global-impression-measure-for-clinical-outcome-assessment-of-nonseizure-symptoms-in-lennox%E2%80%93gastaut-syndrome-and-dravet-syndrome [accessed Jan 9, 2023]."},{"key":"10.1016\/j.yebeh.2023.109173_b0100","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/ejhg.2011.121","article-title":"Copy number variants and infantile spasms: evidence for abnormalities in ventral forebrain development and pathways of synaptic function","volume":"19","author":"Paciorkowski","year":"2011","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.yebeh.2023.109173_b0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13229-019-0280-6","article-title":"Mechanisms underlying the EEG biomarker in Dup15q syndrome","volume":"10","author":"Frohlich","year":"2019","journal-title":"Mol Autism"},{"key":"10.1016\/j.yebeh.2023.109173_b0110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2042098611411127","article-title":"New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?","volume":"2","author":"French","year":"2011","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.yebeh.2023.109173_b0115","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1600-0404.1996.tb00047.x","article-title":"Seizure-inducing effects of antiepileptic drugs: a review","volume":"94","author":"Bauer","year":"1996","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2023.109173_b0120","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1111\/epi.16923","article-title":"Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder","volume":"62","author":"Devinsky","year":"2021","journal-title":"Epilepsia"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023000926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023000926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:49:14Z","timestamp":1761504554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505023000926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":24,"alternative-id":["S1525505023000926"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109173","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE)","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109173"}}